Acquisition Option Agreement with Johnson & Johnson

Bird Rock Bio is a clinical-stage biopharmaceutical company focused on developing innovative immuno-inflammatory regulators. Bird Rock’s lead compound, namacizumab, is a first-in-class, only-in-class negative allosteric modulating antibody to CB1. Namacizumab is the only known negative allosteric modulating antibody (NAMA) to CB1, a well-validated target for NASH. NASH is very rapidly becoming the largest contributor to liver failure and the need for liver transplant. Bird Rock is also developing gerilimzumab, a potentially best-in-class novel anti IL-6 antibody to treat rheumatoid arthritis. Bird Rock’s investors include 5AM Ventures, Versant Ventures, SR One, Apposite Capital, and Aravis.

More Like This

Nov 2023

Merger with Neoleukin Therapeutics (Nasdaq:NLTX)

Exclusive Financial Advisor

View Details >
May 2020
$2 Billion

10-Year Strategic Collaboration with Arcus Biosciences, Inc.

Financial Advisor

View Details >
Oct 2018
Ideal Option

Strategic Investment by Varsity Healthcare Partners

Financial Advisor

View Details >